277 related articles for article (PubMed ID: 33626208)
21. Livin/BIRC7 expression as malignancy marker in adrenocortical tumors.
Altieri B; Sbiera S; Della Casa S; Weigand I; Wild V; Steinhauer S; Fadda G; Kocot A; Bekteshi M; Mambretti EM; Rosenwald A; Pontecorvi A; Fassnacht M; Ronchi CL
Oncotarget; 2017 Feb; 8(6):9323-9338. PubMed ID: 28030838
[TBL] [Abstract][Full Text] [Related]
22. The construction and analysis of tumor-infiltrating immune cells and ceRNA networks in metastatic adrenal cortical carcinoma.
Huang R; Liu Z; Tian T; Song D; Yan P; Yin H; Hu P; Zhu X; Liu Y; Li Z; Meng T; Zhang J; Huang Z
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32175564
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Alternative mRNA Splicing in Adrenocortical Carcinoma.
Liang W; Sun F
Front Endocrinol (Lausanne); 2021; 12():538364. PubMed ID: 33776902
[TBL] [Abstract][Full Text] [Related]
24. Adrenocortical tumors have a distinct, long, non-coding RNA expression profile and LINC00271 is downregulated in malignancy.
Buishand FO; Liu-Chittenden Y; Fan Y; Tirosh A; Gara SK; Patel D; Meerzaman D; Kebebew E
Surgery; 2020 Jan; 167(1):224-232. PubMed ID: 31522749
[TBL] [Abstract][Full Text] [Related]
25. Low Protein Expression of both
Brondani VB; Lacombe AMF; Mariani BMP; Montenegro L; Soares IC; Bezerra-Neto JE; Tanno FY; Srougi V; Chambo JL; Mendonca BB; Almeida MQ; Zerbini MCN; Fragoso MCBV
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513905
[TBL] [Abstract][Full Text] [Related]
26. Wnt/β-catenin activation cooperates with loss of p53 to cause adrenocortical carcinoma in mice.
Borges KS; Pignatti E; Leng S; Kariyawasam D; Ruiz-Babot G; Ramalho FS; Taketo MM; Carlone DL; Breault DT
Oncogene; 2020 Jul; 39(30):5282-5291. PubMed ID: 32561853
[TBL] [Abstract][Full Text] [Related]
27. A Targeted Bioinformatics Assessment of Adrenocortical Carcinoma Reveals Prognostic Implications of GABA System Gene Expression.
Knott EL; Leidenheimer NJ
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33187258
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA expression patterns in adrenocortical carcinoma variants and clinical pathologic correlations.
Duregon E; Rapa I; Votta A; Giorcelli J; Daffara F; Terzolo M; Scagliotti GV; Volante M; Papotti M
Hum Pathol; 2014 Aug; 45(8):1555-62. PubMed ID: 24890943
[TBL] [Abstract][Full Text] [Related]
29. Protein Expression of PTTG1 as a Diagnostic Biomarker in Adrenocortical Carcinoma.
Romero Arenas MA; Whitsett TG; Aronova A; Henderson SA; LoBello J; Habra MA; Grubbs EG; Lee JE; Sircar K; Zarnegar R; Scognamiglio T; Fahey TJ; Perrier ND; Demeure MJ
Ann Surg Oncol; 2018 Mar; 25(3):801-807. PubMed ID: 29218429
[TBL] [Abstract][Full Text] [Related]
30. Impact of the Chemokine Receptors CXCR4 and CXCR7 on Clinical Outcome in Adrenocortical Carcinoma.
Chifu I; Heinze B; Fuss CT; Lang K; Kroiss M; Kircher S; Ronchi CL; Altieri B; Schirbel A; Fassnacht M; Hahner S
Front Endocrinol (Lausanne); 2020; 11():597878. PubMed ID: 33281749
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological and Prognostic Characteristics of CD276 (B7-H3) Expression in Adrenocortical Carcinoma.
Liang J; Liu Z; Pei T; Xiao Y; Zhou L; Tang Y; Zhou C; Wu K; Zhang F; Zhang F; Yin X; Chen N; Wei X; Lu Y; Zhu Y
Dis Markers; 2020; 2020():5354825. PubMed ID: 31998416
[TBL] [Abstract][Full Text] [Related]
32. Targeted Assessment of
Mohan DR; Lerario AM; Else T; Mukherjee B; Almeida MQ; Vinco M; Rege J; Mariani BMP; Zerbini MCN; Mendonca BB; Latronico AC; Marie SKN; Rainey WE; Giordano TJ; Fragoso MCBV; Hammer GD
Clin Cancer Res; 2019 Jun; 25(11):3276-3288. PubMed ID: 30770352
[TBL] [Abstract][Full Text] [Related]
33. Prognosis and Therapeutic Efficacy Prediction of Adrenocortical Carcinoma Based on a Necroptosis-Associated Gene Signature.
Ji D; Zhong R; Fan S
Biomed Res Int; 2022; 2022():8740408. PubMed ID: 35647181
[TBL] [Abstract][Full Text] [Related]
34. Identification of survival-associated alternative splicing events and signatures in adrenocortical carcinoma based on TCGA SpliceSeq data.
Xu N; Ke ZB; Lin XD; Lin F; Chen SH; Wu YP; Chen YH; Wei Y; Zheng QS
Aging (Albany NY); 2020 Mar; 12(6):4996-5009. PubMed ID: 32217810
[TBL] [Abstract][Full Text] [Related]
35. LncRNA HOTAIR participates in the development and progression of adrenocortical carcinoma via regulating cell cycle.
Yan ZC; He L; Qiu JH; Deng WT; Lu JR; Yuan Z; Liu DJ; Zheng RQ; Jiang W
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6640-6649. PubMed ID: 30402836
[TBL] [Abstract][Full Text] [Related]
36. CENPF/CDK1 signaling pathway enhances the progression of adrenocortical carcinoma by regulating the G2/M-phase cell cycle.
Huang YG; Li D; Wang L; Su XM; Tang XB
J Transl Med; 2022 Feb; 20(1):78. PubMed ID: 35123514
[TBL] [Abstract][Full Text] [Related]
37. Identification of hub genes and pathways in adrenocortical carcinoma by integrated bioinformatic analysis.
Guo J; Gu Y; Ma X; Zhang L; Li H; Yan Z; Han Y; Xie L; Guo X
J Cell Mol Med; 2020 Apr; 24(8):4428-4438. PubMed ID: 32147961
[TBL] [Abstract][Full Text] [Related]
38. Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication.
Lippert J; Appenzeller S; Liang R; Sbiera S; Kircher S; Altieri B; Nanda I; Weigand I; Gehrig A; Steinhauer S; Riemens RJM; Rosenwald A; Müller CR; Kroiss M; Rost S; Fassnacht M; Ronchi CL
J Clin Endocrinol Metab; 2018 Dec; 103(12):4511-4523. PubMed ID: 30113656
[TBL] [Abstract][Full Text] [Related]
39. Adrenocortical Carcinoma Steroid Profiles:
Muzzi JCD; Magno JM; Cardoso MA; de Moura J; Castro MAA; Figueiredo BC
Front Endocrinol (Lausanne); 2021; 12():672319. PubMed ID: 34194394
[TBL] [Abstract][Full Text] [Related]
40. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors.
Sbiera S; Schmull S; Assie G; Voelker HU; Kraus L; Beyer M; Ragazzon B; Beuschlein F; Willenberg HS; Hahner S; Saeger W; Bertherat J; Allolio B; Fassnacht M
J Clin Endocrinol Metab; 2010 Oct; 95(10):E161-71. PubMed ID: 20660055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
